TALEN

TALEN1-cyp2r1

ID
ZDB-TALEN-170609-1
Name
TALEN1-cyp2r1
Previous Names
None
Target
Target Sequence 1
5' - CTTGATTCTGCTGGTGA - 3'
ZFIN BLAST NCBI BLAST Ensembl
Target Sequence 2
5' - CGGGGTCTCCGCTGCT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
ihb152 cyp2r1
ihb153 cyp2r1
Expression
Gene expression in Wild Types + TALEN1-cyp2r1
No data available
Phenotype
Phenotype resulting from TALEN1-cyp2r1
No data available
Phenotype of all Fish created by or utilizing TALEN1-cyp2r1
Phenotype Fish Conditions Figures
liver cyp2r1 expression increased amount, abnormal cyp2r1ihb152/ihb152 standard conditions Fig. 2 with image from Peng et al., 2017
liver hk1 expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat ucp1 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
visceral fat mitochondrion decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 6 from Peng et al., 2017
visceral fat mrps10 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
visceral fat mrpl15 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
visceral fat slc25a20 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
visceral fat increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 3 with image from Peng et al., 2017
hypophysis gh1 expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S5 from Peng et al., 2017
liver pklr expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat mtfp1 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
visceral fat pparg expression increased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
subcutaneous fat increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 3 with image from Peng et al., 2017
visceral fat mtfp1 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
liver slc2a2 expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
whole organism decreased size, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 2 with image from Peng et al., 2017
visceral fat mitochondrion membrane potential, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 6 from Peng et al., 2017
liver Ab1-ppargc1a labeling increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S6 from Peng et al., 2017
blood plasma fatty acid increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Table 1 from Peng et al., 2017
whole organism lipid increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 4 with image from Peng et al., 2017
visceral fat pparg expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
visceral fat mrpl2 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
visceral fat Ab1-ppargc1a labeling amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 5 from Peng et al., 2017
visceral fat ppargc1a expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 5 from Peng et al., 2017
whole organism decreased length, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 4 with image,  Table S1 from Peng et al., 2017
female organism lipid increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 3 with image from Peng et al., 2017
visceral fat ppargc1a expression decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 5 from Peng et al., 2017
visceral fat Ab1-ppargc1a labeling decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 5 from Peng et al., 2017
adipose tissue increased amount, abnormal cyp2r1ihb153/ihb153 fasting Fig. S4 with image from Peng et al., 2017
whole organism lipid amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 4 with image from Peng et al., 2017
blood insulin decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 2 from Shao et al., 2022
visceral fat esrra expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
liver gys2 expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat mcu expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
visceral fat ucp1 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
blood glucose increased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 2 from Shao et al., 2022
liver cyp2r1 expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 2 with image from Peng et al., 2017
liver Ab1-mt-co1 labeling increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S7 from Peng et al., 2017
whole organism length, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 4 with image from Peng et al., 2017
liver ghra expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S5 from Peng et al., 2017
pleuroperitoneal cavity fat cell increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 3 with image from Peng et al., 2017
liver igf1 expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S5 from Peng et al., 2017
visceral fat igf1 expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S5 from Peng et al., 2017
liver ugp2a expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat mcu expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
liver insra expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
liver cyp27b1 expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S2 with image from Peng et al., 2017
visceral fat slc25a20 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
liver Ab3-cox4 labeling increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S7 from Peng et al., 2017
visceral fat mrps10 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
liver fbp1a expression increased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
liver cyp27a1.4 expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S2 with image from Peng et al., 2017
blood insulin decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 2 from Shao et al., 2022
visceral fat nrf1 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
whole organism weight, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 4 with image from Peng et al., 2017
blood plasma fatty acid increased amount, abnormal cyp2r1ihb153/ihb153 fasting Table 1 from Peng et al., 2017
visceral fat mrpl2 expression decreased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 6 from Peng et al., 2017
liver ab3-stat5 labeling decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S5 from Peng et al., 2017
male organism lipid increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 3 with image from Peng et al., 2017
visceral fat mitochondrion decreased functionality, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 6 from Peng et al., 2017
liver gck expression decreased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat esrra expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
whole organism decreased weight, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 4 with image,  Table S1 from Peng et al., 2017
liver pck1 expression increased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat Ab3-cox4 labeling decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 6 from Peng et al., 2017
liver g6pc1a.1 expression increased amount, abnormal cyp2r1ihb153/ihb153 chemical treatment by injection: D-glucose Fig. 4 from Shao et al., 2022
visceral fat ghra expression increased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S5 from Peng et al., 2017
blood plasma D3 vitamins decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Table 1 from Peng et al., 2017
visceral fat D3 vitamins decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Table 1 from Peng et al., 2017
liver D3 vitamins decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Table 1 from Peng et al., 2017
blood glucose increased amount, abnormal cyp2r1ihb153/ihb153 control Fig. 2 from Shao et al., 2022
liver cyp24a1 expression decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. S2 with image from Peng et al., 2017
visceral fat nrf1 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
visceral fat mrpl15 expression amount, ameliorated cyp2r1ihb153/ihb153 chemical treatment by environment: calcidiol Fig. 6 from Peng et al., 2017
lipid metabolic process decreased process quality, abnormal cyp2r1ihb153/ihb153 fasting Fig. S4 with image from Peng et al., 2017
visceral fat Ab1-mt-co1 labeling decreased amount, abnormal cyp2r1ihb153/ihb153 standard conditions Fig. 6 from Peng et al., 2017
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.